Compare CMP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMP | GERN |
|---|---|---|
| Founded | 1993 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.1M | 1.0B |
| IPO Year | 2003 | 1996 |
| Metric | CMP | GERN |
|---|---|---|
| Price | $21.99 | $1.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $29.50 | $4.25 |
| AVG Volume (30 Days) | 310.6K | ★ 6.2M |
| Earning Date | 12-07-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ 0.59 | N/A |
| Revenue | N/A | ★ $1,065,000.00 |
| Revenue This Year | $3.43 | $28.49 |
| Revenue Next Year | $3.07 | $44.73 |
| P/E Ratio | $37.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.40 | $1.04 |
| 52 Week High | $34.50 | $2.01 |
| Indicator | CMP | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 36.06 | 39.95 |
| Support Level | $20.93 | $1.08 |
| Resistance Level | $26.72 | $1.26 |
| Average True Range (ATR) | 0.68 | 0.04 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 28.84 | 25.00 |
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.